A retinal hyperspectral imaging biomarker for Alzheimer’s disease: Preliminary study of the influence of eye diseases on imaging scores

Abstract

AbstractBackgroundWe and others have demonstrated that in vivo retinal hyperspectral imaging may serve as a non‐invasive biomarker of brain amyloid beta (Aβ) levels (Hadoux, 2019; More, 2019). We next sought to determine whether individuals with a range of common eye diseases have imaging scores distinct from those of people known to have high Aβ burden on brain PET imaging.MethodRetinal hyperspectral imaging was performed on people presenting to ophthalmology outpatient clinics with visually significant cataracts (n=10), glaucoma (n=18) or diabetic retinopathy (n=14). Hyperspectral imaging scores were calculated for each participant using image processing methods described previously (Hadou..